Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 1

Status

Completed 3

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Prostatic Neoplasms 3Neoplasms, Plasma Cell 3Multiple Myeloma 3Sarcoma 1Osteosarcoma 1

Interventions

Cyclophosphamide 62Dexamethasone 60Melphalan 54Peripheral Blood Stem Cell Transplantation 49Bortezomib 40Busulfan 39fludarabine phosphate 34Filgrastim 32Lenalidomide 30Thalidomide 27Tacrolimus 25Antilymphocyte Serum 23Radiotherapy 22Mycophenolic Acid 17Methotrexate 17Prednisone 15Etoposide 15sargramostim 14Cyclosporine 14fludarabine 12Methylprednisolone 11Granulocyte Colony-Stimulating Factor 11Calcium Dobesilate 11Whole-Body Irradiation 10Doxorubicin 9Carmustine 9pomalidomide 8Vincristine 8Interferon-alpha 8Cord Blood Stem Cell Transplantation 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Neoplasms, Plasma Cell × samarium Sm-153 lexidronam × Clear all
NCT00316940 2013-09-20

Samarium 153 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

National Cancer Institute (NCI)

Phase 1 Completed
36 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00602706 2011-05-16

Samarium Sm 153 Lexidronam Pentasodium and High-Dose Melphalan in Treating Patients With Multiple Myeloma Undergoing Stem Cell Transplant

Mayo Clinic

Phase 1/2 Completed
76 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00478075 2011-05-11

Samarium Sm 153 Lexidronam Pentasodium and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Mayo Clinic

Phase 1/2 Completed
50 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡